Comparative analysis of SGLT2 inhibitors in the treatment of heart failure

Abstract

Heart failure (HF) remains a significant disease with a high risk of complications and mortality, underscoring the need for effective therapeutic approaches. Sodium-glucose cotransporter 2 inhibitors (SGLT2), such as dapagliflozin, empagliflozin, and canagliflozin, have garnered considerable attention as potential remedies for HF. This review is based on a comparative analysis of these SGLT2 inhibitors and their impact on HF. Preliminary data indicate a positive effect in reducing the risk of HF exacerbation and hospitalizations among patients receiving dapagliflozin and empagliflozin. Interestingly, empagliflozin demonstrates potential in reducing the risk of cardiac death and hospitalizations among patients with preserved ejection fraction. This review underscores the significance of further research to deepen the understanding of the mechanisms of action of each drug and their efficacy in different types of heart failure, potentially contributing to personalized patient treatment.